VC-backed Evelo Biosciences goes public
Cambridge, Massachusetts-based Evelo Biosciences, a biotech company, has raised $85 million for its IPO after pricing its 5.3 million shares at $16 per share. The stock began trading May 9, 2018 on the NASDAQ under the ticker symbol "EVLO." Morgan Stanley, Cowen and BMO Capital Markets are the lead underwriters. Evelo's pre-IPO backers included Flagship Pioneering, GV, Celgene, Mayo Clinic and Alexandria Venture Investments.
9 May 2018•2 mins read
